Skip to Content

MD Anderson Events

17th Annual Melvin L. Samuels Lectureship - Recent Advantages in the Co-Clinical Trial Project

17th Annual Melvin L. Samuels Lectureship - Recent Advantages in the Co-Clinical Trial Project

The 17th Annual Melvin L. Samuels Lectureship presents...

Pier Paolo Pandolfi, MD

Recent Advantages in the Co-Clinical Trial Project



Date: 9/13/12, 9am to 10am
Time: 9/13/12, 9am to 10am
Location: AT&T Auditorium, Main Building, Floor 2 (B2.4750)
Format: Lecture
Facilitator: Tatianna Robles
Speaker: Pier Paolo Pandolfi, MD
Speaker Bio: Pier Paolo Pandolfi received his M.D. in 1989 and his Ph.D. in 1996 from the University of Perugia, Italy, after having studied Philosophy at the University of Rome, Italy. He received post-graduate training at the National Institute for Medical Research and the University of London in the UK. Dr. Pandolfi presently holds the Reisman Endowed Chair of Medicine, and is Professor of Pathology at Harvard Medical School. He serves as the Director of Research, Beth Israel Deaconess Cancer Center; Director, Cancer Genetics Program; and Chief, Division of Genetics in the Department of Medicine, Beth Israel Deaconess Medical Center, and is a Member of the Department of Pathology, Beth Israel Deaconess Medical Center. The research carried out in Dr. Pandolfi’s laboratory has been seminal to elucidating the molecular mechanisms and the genetics underlying the pathogenesis of leukemias, lymphomas and solid tumors as well as in modeling these cancers in the mouse. Dr. Pandolfi and colleagues have characterized the function of the fusion oncoproteins and the genes involved in the chromosomal translocations of acute promyelocytic leukemia (APL), as well as of major tumor suppressors such as PTEN and p53, and novel proto-oncogenes such as POKEMON. The elucidation of the molecular basis underlying APL pathogenesis has led to the development of novel and effective therapeutic strategies. As a result of these efforts, APL is now considered a curable disease. Additional novel therapeutic concepts have emerged from this work and are currently being tested in clinical trials. More recently, Dr. Pandolfi and colleagues have presented a new theory describing how mRNA, both coding and non-coding, exerts their biological functions with profound implications for human genetics, cell biology and cancer biology.
Sponsor: Genitourinary Medical Oncology Department
Contact: Tatianna Robles - (713) 563-9349 -